Fulgent Genetics (FLGT) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue was $71 million, with core revenue up 5% year-over-year to $70.2 million, driven by strong growth in precision diagnostics and reproductive health, and supported by recent acquisitions and expanded capabilities in diagnostics and therapeutics.

• Net loss attributable to the company was $8.7 million for Q2 2024, an improvement from Q2 2023, while non-GAAP income was $4.7 million ($0.15 per share).

• All laboratory service business areas—precision diagnostics, anatomic pathology, and biopharma services—posted quarter-over-quarter growth for the first time since 2022, with precision diagnostics leading at 35% year-over-year growth.

• Significant progress in therapeutic development, including phase 1 data for FID-007 in head and neck cancer, advancement of FID-022 and ADC programs, and initial enrollment in a phase 2 trial.

• Integration of Inform Diagnostics and relocation to a new 96,000 sq ft lab in Coppell, Texas, expected to triple capacity and improve efficiency.

Financial highlights

• Q2 2024 revenue was $71 million, up 5% year-over-year; core revenue was $70.2 million.

• GAAP gross margin was 37%, non-GAAP gross margin 40.1%, both improving year-over-year.

• Adjusted EBITDA loss narrowed to $727,000; GAAP net loss was $8.7 million, and non-GAAP income was $4.7 million.

• Cash, cash equivalents, and investments totaled $837.9 million as of June 30, 2024.

• LTM operating cash flow as of Q2 2024 was $37 million.

Outlook and guidance

• 2024 core revenue guidance reiterated at $280 million, representing 7% year-over-year growth.

• Non-GAAP gross margins expected to remain in the high 30% range, targeting 40% by year-end.

• Non-GAAP operating margin expected at approximately -16% for 2024; improved 2024 non-GAAP loss guidance to $(0.30) per share.

• Anticipated year-end cash balance of $800 million, excluding extraordinary expenditures.

• No revenue expected from therapeutics development in 2024; cash burn for this segment projected at $15–$17 million.